SGR-0320

N/A

Report date: 2025/12/31 17:07:09

Base Information

Drug NameSGR-0320
Drug Alias NameLRRK2 inhibitor therapy(Schrodinger)SGR-0320
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson DiseaseNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSchrodinger Inc
China Registration ClassN/A

Develop Information

Active CompaniesSchrodinger Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A